---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-24-000008"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T22:29:14.026074+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical announces Renuvion study shows significantly fewer adverse events vs InMode RF

## Summary
- Retrospective study of 450+ patients: 229 Renuvion vs 236 InMode Bipolar RF; statistically fewer adverse events (p<.0001).
- Adverse events included burns, hematoma, hypertrophic scar, and seroma; Renuvion group had significantly less.
- Renuvion featured in three educational sessions at AACS 40th Annual Scientific Meeting, Feb 22-24, 2024.
- Dr. Michael Kluska presents the study; CEO Charlie Goodwin highlights expansion of clinical evidence supporting safety.

## SEC filing metadata
- accession: 0000719135-24-000008
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913524000008/0000719135-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913524000008/apyx-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-24-000008
- JSON: https://secwatch.observer/filing/0000719135-24-000008.json
- Plain text: https://secwatch.observer/filing/0000719135-24-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.